The FreeStyle Libre 3 system and FreeStyle Libre 2 system are indicated for use in people with diabetes age 4 and older.
Freestyle Libre 2 Plus sensor and 3 Plus sensor are indicated for use in people with diabetes age 2 and older.
Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.
* Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.
† or ♢ Eligible patients will receive one (1) FreeStyle Libre 2 system sensor or (1) FreeStyle Libre 3 system sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1 diabetes or Type 2 diabetes or gestational diabetes. Patients ages 18 and older are eligible to sign up and receive an offer for the (1) FreeStyle Libre 2 system sensor or (1) FreeStyle Libre 3 system sensor. Patients ages 4-17 are eligible to receive an offer for the (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor through their parent or guardian. Patients ages 2-17 are eligible to receive an offer for the (1) FreeStyle Libre 2 Plus sensor or (1) FreeStyle Libre 3 Plus sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Kaiser Permanente, Medicare, Medicaid or other federal or state healthcare programs, residents of Massachusetts, or US territories (other than Puerto Rico). The free (1) FreeStyle Libre 2 system sensor or (1) FreeStyle Libre 3 system sensor is provided as a sample and is limited to one sample per eligible person per product identification number. The FreeStyle Libre 2 system sensor or FreeStyle Libre 3 system sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.
‡ Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.
§ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products.
II Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User’s Manual for more information.
¶ Notifications will only be received when alarms are turned on and the sensor is within 20 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 2 User’s Manual for more information.
# The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. LibreLinkUp is not intended to be used for dosing decisions. The user should follow instructions on the continuous glucose monitoring system. LibreLinkUp is not intended to replace self-monitoring practices as advised by a physician.
** The user's device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.
†† The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
‡‡ 60-minute warm-up required when starting the sensor.
§§ Based on patient applied FDA cleared integrated CGMs to be used by adults and children replacing blood glucose testing for diabetes treatment decisions.
IIII FreeStyle Libre 3 system is cleared to be used by children 4 years and older with Libre 3 sensor and 2 years and older with Libre 3 Plus sensor.
¶¶ Multicenter study evaluating sensor data from FreeStyle Libre 3 and Dexcom G7 compared to blood plasma glucose under real world conditions. Study limitations: Study subjects followed their daily routines and were not exposed to risks of hyperglycemia or hypoglycemia manipulations, neither sensor was evaluated for accuracy during times of rapidly changing glucose. Outcome measures: Differences in mean absolute relative difference, number and percentage of matched glucose pairs within ±20 mg/dL/±20% of reference values. Results from 55 subjects (minimum required sample size: 42). Registration in clinicaltrials.gov is not required as the study does not meet the definition of Applicable Clinical Trial. Study funding provided by Abbott.
## Among patient-applied sensors.
*** In comparison with Dexcom G7 and Medtronic Guardian Connect System User Guide.
††† The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.
‡‡‡ The FreeStyle Libre 3 app is designed to facilitate data sharing between patients and their healthcare providers and caregivers.
§§§ Glucose alarms will transfer to the LibreLinkUp app users when users are connected and alarms are enabled on the FreeStyle Libre 2 app.
IIIIII Based on a comparison of list prices of the FreeStyle Libre personal CGM systems versus competitors’ CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
¶¶¶ Based on prescription claims for the aggregate of patients covered by Commercial insurance, Managed Medicare, Managed Medicaid using the FreeStyle Libre personal CGM systems versus competitors’ CGM systems. Does not include fee-for-service Medicare, fee-for-service Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre personal CGM systems require a prescription.
References: 1. Data on file. Abbott Diabetes Care, Inc. 2. Campbell, Fiona M., et al. "Outcomes of using flash glucose monitoring technology by children and young people with Type 1 diabetes in a single arm study." Pediatric Diabetes 19, no. 7 (2018): 1294-1301. https://doi.org/10.1111/pedi.12735. 3. FreeStyle Libre 2 User's Manual. 4. FreeStyle Libre 3 User's Manual. 5. Based on FreeStyle Libre 3 User's Manual, Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide. 6. Hanson, K. "Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems." J Diabetes Sci Technol 18, no. 3 (2024): 598-607. https://doi.org/10.1177/19322968231225676. 7. Unger, Jeff, Pamela Kushner, and John E. Anderson. “Practical Guidance for Using the FreeStyle Libre Flash Continuous Glucose Monitoring in Primary Care.” Postgraduate Medicine 132, no. 4 (2020): 305–313. https://doi.org/10.1080/00325481.2020.1744393.
ADC-33111 v7.0
